Epigenetics Market Size, Share, Growth Analysis, By Product type (Reagents, Kits, Instruments, Enzymes), By Technology (DNA Methylation, Histone Methylation, Histone Acetylation, MicroRNA Modification), By Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Neurological Disorders), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35H2201 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 96 | Figures: 76

Epigenetics Market News

in Epigenetics Market

In December 2023, Biolabs and Promega expanded their joint efforts to accelerate life science innovation globally by supporting early-stage startups. Waldorf-based Promega GmbH, a subsidiary of the German subsidiary of global life sciences company Promega, provides equipment, services and training to Biolabs Heidelberg.
In November 2023, QIAGEN and Element Biosciences, Inc. entered into a joint venture. made a collaborative effort. has strategically delivered a complete NGS workflow for the new Element AVITI System.
In October 2023, Zenith Epigenetics Ltd. acquired 1,000 shares of the stock. and Cencora reached an agreement to commercialize the ZEN-3694 program, an epigenetic approach to enhance the performance of drugs currently marketed for the treatment of cancer.

Epigenetics Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Epigenetics Market size was valued at USD 1.36 billion in 2022 and is poised to grow from USD 1.6 billion in 2023 to USD 4.7 billion by 2031, growing at a CAGR of 14.8% in the forecast period (2024-2031).

The epigenetics market is characterized by a dynamic and competitive landscape, with a mix of established players and emerging biotech companies driving innovation and growth. Key market participants are increasingly focusing on research and development (R&D) to develop novel epigenetic therapies and diagnostics, capitalizing on the rising interest in personalized medicine and targeted therapies. 'AbbVie Inc.', 'AstraZeneca PLC', 'Bayer AG', 'BeiGene Ltd.', 'Bristol Myers Squibb Company', 'Epizyme, Inc.', 'GlaxoSmithKline PLC', 'Incyte Corporation', 'Johnson & Johnson', 'Merck & Co., Inc.', 'Novartis AG', 'Pfizer Inc.', 'Regeneron Pharmaceuticals, Inc.', 'Roche Holding AG', 'Seattle Genetics, Inc.', 'Takeda Pharmaceutical Company Limited', 'Targovax, Inc.', 'Vertex Pharmaceuticals Incorporated', 'Vivid Biosciences Inc.', 'Zymeworks Inc.'

One of the major drivers of the epigenetics market is the rising prevalence of cancer and other chronic diseases such as cardiovascular disease. Epigenetic modifications such as DNA methylation and histone modifications play an important role in growth and development occurring in these diseases. Significant investments in monetary and medical development have been stimulated e.g. as precision medicine becomes increasingly prominent, epigenetic therapies offer promising potential for personalized therapies, driving the demand for epigenetic products and services.

A major trend in the epigenetics market is the development of advanced epigenetic editing technologies, such as CRISPR/Cas9-based tools, which allow precise modification of epigenetic marks. This technology allows researchers to modify specific genes without altering the underlying DNA sequence, opening new opportunities to study gene regulation and develop new therapies. Growing adoption of these tools is expected to revolutionize epigenetic research and expand treatment possibilities in areas such as cancer, neurological diseases and autoimmune disorders.

North America dominated the market, with a share of 38.19% in 2023. The region is growing due to public awareness, improved pharmaceutical facilities and huge investments in R&D. Besides, prevalent chronic diseases and heavy investments by market players in epigenetic research, making it a promising environment for further growth. The presence of major players such as; Elemental Biological Sciences, Inc.; Dovetail Genomics LLC.; Illumina, Inc.; And in the U.S. market, Promega Corporation is expected to support regional expansion. It is expected that the epigenetics market will surge during the forecast period as chronic diseases prevail and increased investment by market players in epigenetics fuels regional growth. For example, epigenetic editing consumes another genomic medicine company, Croma Medicine, Inc.; (Croma) face million invested in US$.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Epigenetics Market News

Epigenetics Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Epigenetics Market?

Who are the key vendors in the Epigenetics Market?

What is the key driver of Epigenetics Market?

What is the key market trend for Epigenetics Market?

Which region accounted for the largest share in Epigenetics Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300